Outpatient combination chemoimmunotherapy for patients with metastatic melanoma

Kashani‐Sabet, Mohammed; Sagebiel, Richard W.; Collins, Henry E.; Glassberg, Alan B.; Allen, Robert E.; Leong, Stanley P. L.; Small, Eric J.

doi:10.1002/(sici)1097-0142(19991115)86:10<2160::aid-cncr40>3.0.co;2-w

Cited by 8 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The capacity of cancer chemotherapeutic agents to cause immunosuppression is widely recognized. In addition to their immunosuppressive properties, many chemotherapeutic drugs, like cisplatin,45, 46 and cyclophosphamide40, 47 also augment the immune response when used at low doses that are not cytotoxic, a phenomenon that has been extensively documented over the past several decades. Glaser48 showed that treatment with low doses of cyclophosphamide reduced the regulatory T cell effect, thus promoting the differentiation of antigen specific cytotoxic T‐lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts

Ara

Baher

Storm

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts

Ara

Baher

Storm

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

“…In our study, IL-2 was administered intravenously on days 3 and 4 only, on the subsequent days the subcutaneous route of administration was chosen to allow patients self-administration of IL-2 at home. Although efficacy of subcutaneous IL-2 was demonstrated in several combination studies with chemotherapy and/or IFNα (Atzpodien et al, 1990;Hoffmann et al, 1998;Kashani-Sabet et al, 1999), data on the activity of IL-2 applied subcutaneously as a monotherapy are limited (Atzpodien et al, 1990;Schomburg et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

Hauschild¹,

Garbe

Stolz³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

In several phase II-trials encouraging tumour responses rates in advanced metastatic melanoma (stage IV; AJCC-classification) have been reported for the application of biochemotherapy containing interleukin 2. This study was designed to compare the efficacy of therapy with dacarbazine (DTIC) and interferon α (IFN-α) only to that of therapy with DTIC and IFN-α with the addition of interleukin 2 (IL-2) in terms of the overall survival time and rate of objective remissions and to provide an elaborated toxicity profile for both types of therapy. 290 patients were randomized to receive either DTIC (850 mg/m 2 every 28 days) plus IFN-α2a/b (3 MIU/m 2 , twice on day 1, once daily from days 2 to 5; 5 MIU/m 2 3 times a week from week 2 to 4) with or without IL-2 (4.5 MIU/m 2 for 3 hours i.v. on day 3; 9.0 MIU/m 2 i.v. day 3/4; 4.5 MIU/m 2 s.c. days 4 to 7). The treatment plan required at least 2 treatment cycles (8 weeks of therapy) for every patient. Of 290 randomized patients 281 were eligible for an intention-to-treat analysis. There was no difference in terms of survival time from treatment onset between the two arms (median 11.0 months each). In 273 patients treated according to protocol tumour response was assessable. The response rates did not differ between both arms ( P = 0.87) with 18.0% objective responses (9.7% PR; 8.3% CR) for DTIC plus IFN-α as compared to 16.1% (8.8% PR; 7.3% CR) for DTIC, IFN-α and IL-2. Treatment cessation due to adverse reactions was significantly more common in patients receiving IL-2 (13.9%) than in patients receiving DTIC/IFN-α only (5.6%). In conclusion, there was neither a difference in survival time nor in tumour response rates when IL-2, applied according to the combined intravenous and subcutaneous schedule used for this study, was added to DTIC and IFN-α. However, toxicity was increased in melanoma patients treated with IL-2. Further phase III trials with continuous infusion and higher dosages must be performed before any final conclusions can be drawn on the potential usefulness of IL-2 in biochemotherapy of advanced melanoma. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Eggermont

Kirkwood

2004

European Journal of Cancer

318

163

View full text Add to dashboard Cite

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma

Cited by 8 publications

References 12 publications

Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts

Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

Contact Info

Product

Resources

About